Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
4.260
-0.390 (-8.39%)
Oct 25, 2024, 4:00 PM EDT - Market closed
Company Description
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases.
It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy.
The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024.
Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Climb Bio, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Aug 10, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Aoife Brennan |
Contact Details
Address: PMB #117, 2801 Centerville Road, 1st Floor Wilmington, Delaware 19808-1609 United States | |
| Phone | 866 857 2596 |
| Website | eliemtx.com |
Stock Details
| Ticker Symbol | CLYM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001768446 |
| ISIN Number | US28658R1068 |
| Employer ID | 83-2273741 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | Chief Executive Officer, President and Director |
| Dr. Brett Kaplan M.B.A., M.D. | Chief Operating Officer and Principal Financial Officer |
| Emily Pimblett | Chief Accounting Officer |
| Jo Palmer-Phillips Ph.D. | Chief Development Officer |
| Dr. Nishi Rampal M.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 15, 2024 | 8-K | Current Report |
| Oct 2, 2024 | 8-K | Current Report |
| Aug 27, 2024 | 8-K | Current Report |
| Aug 26, 2024 | 8-K | Current Report |
| Aug 16, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 14, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Jul 23, 2024 | EFFECT | Notice of Effectiveness |
| Jul 23, 2024 | 424B3 | Prospectus |